News stories about Arrowhead Pharmaceuticals (NASDAQ:ARWR) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.1099574182289 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Arrowhead Pharmaceuticals (ARWR) opened at $6.56 on Tuesday. The stock has a market capitalization of $569.33, a PE ratio of -13.96 and a beta of 2.52. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.87 and a quick ratio of 3.87. Arrowhead Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $6.75.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $8.71 million during the quarter, compared to analysts’ expectations of $7.32 million. Arrowhead Pharmaceuticals had a negative return on equity of 42.52% and a negative net margin of 116.17%. equities analysts anticipate that Arrowhead Pharmaceuticals will post -0.72 EPS for the current fiscal year.
In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 1st. The stock was sold at an average price of $3.69, for a total value of $73,800.00. Following the transaction, the chief operating officer now directly owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.60% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.